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Dystroglycanopathy is a major class of congenital muscular dystrophy that is caused by a deficiency of
functional glycans on a-dystroglycan (a-DG) with laminin-binding activity. A product of a recently
identified causative gene for dystroglycanopathy, AGO61, acted in vitro as a protein O-mannose b-1,
4-N-acetylglucosaminyltransferase, although it was not functionally characterized. Here we show the
phenotypes of AGO61-knockout mice and demonstrate that AGO61 is indispensable for the formation of
laminin-binding glycans of a-DG. AGO61-knockout mouse brain exhibited abnormal basal lamina
formation and a neuronal migration defect due to a lack of laminin-binding glycans. Furthermore, our
results indicate that functional a-DG glycosylation was primed by AGO61-dependent GlcNAc
modifications of specific threonine-linked mannosyl moieties of a-DG. These findings provide a key
missing link for understanding how the physiologically critical glycan motif is displayed on a-DG and
provides new insights on the pathological mechanisms of dystroglycanopathy.
C
ongenital muscular dystrophies and limb-girdle muscular dystrophies are clinically and genetically het-
erogeneous degenerative diseases that primarily affect voluntary muscles. Dystroglycanopathy is a group
of these diseases associated with brain and eye abnormalities at the severe end of the clinical spectrum,
including Walker–Warburg syndrome (WWS), muscle-eye-brain (MEB) diseases, Fukuyama-type congenital
muscular dystrophy (FCMD), and congenital muscular dystrophy type 1D (MDC1D). The hallmark of these
diseases is hypoglycosylation of a-dystroglycan (a-DG)1,2, which along with b-DG is cleaved from a precursor
protein encoded for by a single gene by post-translational processing3. A dystrophin glycoprotein complex that is
formed from several intracellular, transmembrane, and extracellular proteins including a- and b-DG subunits
connects the cytoskeleton of a muscle fiber to surrounding extracellular matrix components, such as laminin,
agrin, and perlecan, depending on the glycosylation status of a-DG4,5.
To date, 13 genes have been identified that are associated with dystroglycanopathies, among which 8 genes
have been characterized as those encoding enzymes responsible for the formation of the functional a-DG glycans.
Protein O-mannosyltransferase 1 (POMT1)6, POMT27,8, and protein O-mannose b-1,2-N-acetylglucosaminyl-
transferase 1 (POMGnT1)9 along with GDP-mannose pyrophosphorylase (GMPPB)10 are involved in the bio-
synthesis of O-mannosyl glycans on a-DG. The outer regions of laminin-binding glycans consist of Xyl-GlcA
repeat sequences, the formation of which is catalyzed by like-acetylglucosaminyltransferase (LARGE), a causative
gene product forMDC1D11,12. Furthermore, phosphorylatedO-mannosylation was identified on recombinant a-
DG, the laminin-binding glycans of which were shown to be degraded by HFaq treatment that hydrolyzes
phosphoester linkages13. Thus, the laminin-binding region is presumably linked to a-DG through post-phos-
phoryl O-manosylation. However, the functionally relevant glycan structure of a-DG has not been well deli-
neated, notwithstanding that several mutants associated with dystroglycanopathy have been identified in
fukutin14, fukutin-related protein (FKRP)15, UDP-GlcNAc:bGal b-1,3-N-acetylglucosaminyltransferase 1
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(B3GNT1)16, isoprenoid synthase domain containing (ISPD)17–19,
and transmembrane protein 5 (TMEM5)19, which are associated with
impaired formation of a-DG laminin-binding glycans.
Recently, AGO61 (also known as GTDC2) was newly identified as
a causative gene product associated with WWS based on the results
of whole-exome sequencing, homozygosity mapping, and morpho-
lino-mediated knockdown of an AGO61 zebrafish ortholog20. It was
subsequently characterized as a protein O-mannose b-1,4-N-acetyl-
glucosaminyltransferase (POMGnT2) based on its in vitro enzymatic
activities against a synthetic peptide substrate carrying a single O-
Man21. Although a further b3GalNAc-extended and phosphorylated
GlcNAcb1-4Man-O- unit by b-1,3-N-acetylgalactosaminyltransfer-
ase 2 (B3GALNT2)21,22 and protein kinase-like protein SGK19621,23,
respectively, was inferred to be essential for the formation of func-
tional laminin binding glycans on aDG, the precise roles of AGO61
in vivo remain to be determined. Here, we characterized the pheno-
types of AGO61-knockout mice and determined that AGO61
mediated the formation of laminin-binding glycans on a-DG.
Results
AGO61-knockoutmice exhibit abnormal neuronalmigration.We
subjected the mouse AGO61 locus to targeted disruption. A null
allele was generated by replacing the first coding exon with a
neomycin resistance gene (Supplementary Fig. S1a). Mice that
were heterozygous for the AGO61 mutation appeared grossly
normal and were fertile. The progeny of a heterozygous intercross
had an approximately 15251 ratio of wild type and heterozygous
AGO61, and a homozygous AGO61 ratio that was indicative of
Mendelian inheritance. However, the newborns of homozygotes
were slightly smaller than the other genotypes and died within the
first day of birth (Fig. 1a and b).
AGO61 is mainly expressed in the central nervous system20.
AGO61-knockout mouse brains exhibited abnormal basal lamina
formation and the radial glia endfoot had detached from the basal
membrane (Fig. 1c). Moreover, nuclear staining revealed defects in
neuronal migration and laminar organization in the AGO61-KO
mouse cerebral cortex (Fig. 1c). These neurodevelopmental abnor-
malities are commonly seen in dystroglycanopathy mouse mod-
els24–26, which suggested an essential role for AGO61 in the
functional maturation of a-DG in vivo.
AGO61 is indispensable for the formation of laminin-binding
glycans of a-DG. For biochemical analysis, we enriched DG from
mouse embryonic brains (embryonic day 17.5) with wheat germ
agglutinin (WGA) beads and then performed laminin overlay and
Western blot analyses using IIH6, which recognizes laminin-binding
glycans on a-DG, and anti-a-DG core antibodies. AGO61-KO
embryonic mouse brains exhibited a-DG hypoglycosylation, which
indicated a lack of laminin-binding glycans (Fig. 2a). An immu-
noreactive band of an a-DG core of AGO61-KO mice migrated to
a position similar to that of control mouse a-DG treated with HFaq
(Fig. 2b). Furthermore, there were no significant differences between
WT and KO mice brains in the expression levels of other dystro-
glycanopathy-associated genes (Fig. 2c). These results indicated that
AGO61was involved in the formation of laminin-binding glycans on
a-DG.
To confirm these findings, we expressed the AGO61 protein in
AGO61-deficientmouse embryonic fibroblasts (MEFs). AGO61 pro-
tein expression rescued the defect in laminin-binding glycans,
whereas mutants with alleles associated with WWS (R158H and
R445stop)20 had no rescue capability (Fig. 2d). Although it has been
reported that several dystroglycanopathy models with mutations in
POMGnT1, LARGE, or fukutin could be recovered by LARGE over-
expression, laminin-binding glycans were not rescued by LARGE
overexpression in AGO-deficient MEFs (Fig. 2e). LARGE is located
in the Golgi apparatus and is responsible for the formation of the
Figure 1 | AGO61-KO mice exhibit neuron migration defects. (a) Phenotypes of AGO61 KO and WT pups at embryonic day 17.5. (b) Body
weights of wild type (WT), heterozygous (hetero), andKOpups at postnatal day 0 (n5 4–6 for each genotype). Results aremeans6 SDs. (c) Brain sagittal
sections fromAGO61-KO andWTpups at embryonic day 17.5 were stained with anti-nestin and anti-laminin antibodies used as primary antibodies, and
then with Alexa Fluor 488-conjugated anti-rat IgG (green) and Alexa Fluor 595-conjugated anti-rabbit IgG (red) used as secondary antibodies,
respectively. Nuclei were stained with DAPI (blue).
www.nature.com/scientificreports
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Figure 2 | AGO61 is indispensable for the formation of laminin-binding glycans of a-DG. (a) WGA-enriched brain lysates prepared from WT and
AGO61-KO pups at embryonic day 17.5 were subjected to laminin overlay and immunoblot analysis using IIH6, anti a-DG core, and anti-b-DG
antibodies. The full-length blot with anti-b-DG antibody is presented in Supplementary Fig. S7a. (b) Chemical dephosphorylation of a-DG fromWGA
enriched brain lysates. Brain lysates were treated with HFaq and then analyzed by laminin overlay and Western blot using IIH6 and anti a-DG core
antibodies. (c) mRNA expression of DAG1, LARGE, LARGE2, POMGnT1, POMT1, POMT2, fukutin, FKRP, B3GNT1, ISPD, and GAPDH in brain
tissue from WT and AGO61 KO pups at embryonic day 17.5 were analyzed by RT-PCR. GAPDH was used as an internal control. (d) AGO61 and its
mutants with loss-of-function mutations were transfected into AGO61-deficient MEFs. Cell surface proteins were biotinylated, pull down, and analyzed
by laminin overlay and Western blot with anti a-DG core and b-DG antibodies. Cell lysates were also analyzed for AGO61 expression by Western blot
using an anti-AGO61 antibody. The full-length blots with anti-b-DG and anti-AGO61 antibodies are presented in Supplementary Figs. S7b and S7c,
respectively. (e) LARGE was transfected into control (1/1) or AGO61-deficient (2/2) MEFs. Cell surface proteins were biotinylated, pulled down, and
analyzed by laminin overlay and Western blot using anti a-DG core and b-DG antibodies. Cell lysates were analyzed for LARGE-HA expression by
Western blot using an anti-HA antibody. The full-length blots with anti-b-DG and anti-HA antibodies are presented in Supplementary Figs. S7d and S7e,
respectively.
www.nature.com/scientificreports
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Figure 3 | AGO61 modifies GlcNAc residues at specific sites on a-DG. (a) a-DG-Fc was transiently transfected with or without AGO61 into COS1
cells. a-DG-Fc recombinant proteins were collected from cell lysates and culture media using protein A resin and analyzed for laminin overlay and
Western blot using anti-Fc and anti-O-GlcNAc antibodies. (b) a-DG373-HALO and its mutant T317A/T319A were transiently transfected with or
without LARGE-myc intoCOS7 cells. HALO-fused proteins were collected frommediumusingHALO resin followed by digestionwith TEVprotease and
then analyzed by laminin overlay. Cell lysates were analyzed for the expression of HALO-fused proteins and LARGE-myc by Western blot using anti-
HALO and anti-myc antibodies. The full-length blots with anti-HALO and anti-myc antibodies are presented in Supplementary Figs. S7f and S7g,
respectively. (c) a-DG373-HALO and its mutant T317A/T319A were transiently transfected with or without AOG61 into COS7 cells. HALO-fused
proteins were collected from the cell lysates using HALO resin followed by digestion with TEV protease and then analyzed by Western blot using an
anti-O-GlcNAc antibody (CTD110.6). The cell lysates were analyzed for the expression of HALO-fused proteins and AGO61 byWestern blot using anti-
HALO and anti-AGO61 antibodies. The full-length blots with anti-HALO and anti-AGO61 antibodies are presented in Supplementary Figs. S7h and S7i,
respectively.
www.nature.com/scientificreports
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functional Xyl-GlcA repeats of laminin-binding glycans12,27,28,
whereas AGO61 was localized in the endoplasmic reticulum (ER)
(Supplementary Fig. S2), consistent with the previously reported
result obtained with HEK293 cells21. These results indicated that
AGO61 was actively involved in an early stage of laminin-binding
glycan formation.
AGO61 modifies GlcNAc residues at specific sites on a-DG.Most
recently, it was reported that AGO61 had POMGnT activity,
which contributed to the formation of a previously identified pho-
sphorylated O-mannosyl trisaccharide [GalNAc-b3-GlcNAc-b4-
(phosphate-6-)Man]21. However, AGO61 belongs to the GT61
family, which includes the recently identified extracellular protein
O-b-N-acetylglucosaminyltransferase. To detect all likely GlcNAc
modifications by AGO61, we used an anti-O-GlcNAc antibody
(clone: CTD110.6) with known wide cross-reactivity, including
reactivity against terminal GlcNAc-b1-4GlcNAc29 (Fig. 3a). AGO61-
dependent GlcNAc modification was detected by CTD110.6 but not
by another anti-O-GlcNAc antibody (HGAC85) (Supplementary
Fig. S3). Interestingly, AGO61-dependent GlcNAc modifications
were detected in a-DG-Fc prepared from cell lysates but not in
those secreted into the medium irrespective of HFaq treatment
(Fig. 3a and Supplementary Fig. S4).
To identify the AGO61-dependent GlcNAc modification sites on
a-DG, we generated 3 types of a-DG deletion mutants with C-ter-
mimal HALO tags (Supplementary Fig. S5). AGO61-dependent
GlcNAc modifications were detected in all these mutants, which
indicated that the modification had occurred in the N-terminal 62-
residue segment of themucin-like domain. This domain contains the
previously identified sites (Thr-317 and Thr-319) that display the
laminin-binding glycans produced by LARGE30. Using a-DG373
and its T317A/T319A mutant, we confirmed that these threonine
residues displayed laminin-binding glycans (Fig. 3b). Interestingly,
the T317A/T319A mutant of a-DG373 exhibited little GlcNAc
modification despite AGO61 expression (Fig. 3c).
Moreover, by LC-MS/MS analysis of the tryptic glycopeptides
derived from recombinant a-DG428 expressed in the presence or
absence of AGO61 in COS7 cells, among other glycoforms, we
detected one that carried three Hex, two HexNAc, and a phosphory-
lated Hex (PHex) on QIHA317TP319TPVTAIGPPTTAIQEPPSR
(Fig. 4). In accordance with the substrate specificity of SGK196,
which phosphorylates the trisaccharide GalNAcb-3GlcNAcb-
4Man but not the single Man21, the detected b6 1 PHex ion localized
the phosphorylated trisaccharide at T317. This was corroborated by
the b13 ions that carried an intact HexNAc2PHex moiety and Hex-
containing y4 and y13 ions, which localized the additional O-Hex
substituents at the C-terminal half distal from T317.
AGO61 is a priming enzyme for the formation of laminin-binding
glycans. LARGE-dependent hyperglycosylation was undetectable
for the T317A/T319A mutant of a-DG373, whereas the formation
of laminin-binding glycans was slightly enhanced when LARGE was
co-overexpressed with AGO61 (Fig. 5a). This indicated that an
alternate O-Man residue(s) within a-DG373 (other than T317 and
T319) was utilized as the LARGE-dependent modification site by the
action of AGO61. Based on this result, we hypothesized that AGO61
was a key regulator for the expression of a laminin-binding glycan on
a specific O-Man residue. To test this, we used Dmucin1-Fc, an a-
DG-Fcmutant with only onemajor LARGE-dependentmodification
site, Thr-379, as it lacked Arg311 through Ile37031. As expected, a
T379A mutant of Dmucin1-Fc (Dm1-T379A) barely exhibited any
laminin-binding activity even under LARGE-overexpression con-
ditions (Fig. 5b). However, LARGE and AGO61 co-overexpression
resulted in the production of an IIH6-positive laminin-binding
glycan on Dm1-T379A. Moreover, this effect was not observed
with an AGO61 mutant (R158H) and several other dystroglycano-
pathy-associated gene products, including fukutin and FKRP. This
supported our hypothesis that AGO61 was the priming enzyme
required for determining candidate sites where a laminin-binding
glycan was formed.
Figure 4 | Determination of the presence of a phosphorylated trisaccharide on T317 of a-DG428 co-expressed with AGO61 in COS7 cells.
a-DG428 was purified using aHaloTag protein purification system from cell lysates co-transfected with a-DG428-HALO and AGO61, separated by SDS-
PAGE, and in-gel digested with trypsin (Supplementary Fig. S6). The extracted peptides/glycopeptides were directly analyzed by LC-MS/MS. The
successive neutral losses of HexNAc and PHex from both the doubly and triply charged molecular ions overlapped with those of the additional Hex and
collectively defined them/z of the bare peptide core with the fitted P1Hex4HexNAc2 glycosyl composition. The y41Hex and y131Hex1-3 fragment ions
localized the additional 3 Hex on the C-terminal half of the peptide, whereas the b13 1 PHex 1 HexNAc1-2 ions established the HexNAc2PHex
substituent on theN-terminal half alongwith the b61PHex ion that further identified it on T317, as annotated. Key: Pep, peptide core; circle andH,Hex;
square and N, HexNAc; P, phospho-; pH, phosphorylated Hex; M, molecular ion.
www.nature.com/scientificreports
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Figure 5 | Laminin-binding glycans are primed by an AGO61-dependent GlcNAc modification. (a) a-DG373-HALO and its mutant T317A/T319A
were transiently transfected with or without AOG61 and LARGE-myc into COS7 cells. HALO-fused proteins were collected using HALO resin followed
by digestionwith TEV protease and then analyzed by laminin overlay. Cell lysates were analyzed for the expression ofHALO-fused proteins, LARGE-myc,
and AGO61 by Western blot using anti-HALO, anti-myc, and anti-AGO61 antibodies. The full-length blots with anti-HALO, anti-myc, anti-AGO61
antibodies are presented in Supplementary Figs. S7j, S7k, and S7l, respectively. (b) Dmucin1-Fc and Dm1-T379A were transiently transfected with or
without fukutin-myc, FKRP-FLAG, AGO61-V5, and AGO61-R158H-mutant-V5 (R158H-V5) into LARGE overexpressing COS1 cells. Secreted proteins
were pulled down from the culture medium and analyzed by laminin overlay assay andWestern blot using IIH6 and anti-Fc antibodies (medium). Anti-
Fc antibody was used to monitor protein loading. Cell lysates were analyzed for the expression of LARGE-myc, fukutin-myc, FKRP-FLAG, and AGO61-
V5 by Western blot using anti-myc, anti-FLAG, and anti-AGO61 antibodies. The full-length blots with anti-Fc, anti-FLAG and anti-AGO61 antibodies
are presented in Supplementary Figs. S7m, S7n and S7o, respectively.
www.nature.com/scientificreports
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Discussion
AGO61-KO mice lacked laminin-binding glycans and exhibited
phenotypes similar to those of known dystroglycanopathy mutants,
as reflected by abnormalities in neural migration and basal lamina
formation (Figs. 1 and 2). These defects were also observed in dys-
troglycanopathy mouse models with mutations of DG, fukutin,
B3GNT1, or ISPD, due to a lack of laminin-binding glycans dis-
played on a-DG24–26. Our results show, firstly, that AGO61 is indis-
pensable for the formation of laminin-binding glycans.
Although it has been shown that the laminin-binding glycans of
a-DG are extended through a phosphodiester linkage and phos-
phorylatedO-Man was identified on recombinant a-DG, their entire
structures from the innermost O-Man to the outer post-phosphoryl
moiety have not been established. It was suggested that the formation
of a phosphorylated O-mannosyl trisaccharide, GalNAc-b3-
GlcNAc-b4-(phosphate-6-)Man, as catalyzed by AGO61, B3GA-
LNT2, and SGK19621, served as the base for the extension of
laminin-binding glycans. More specifically, AGO61 can attach a b-
GlcNAc moiety at the 4-position of a-DG-O-mannose, which is
followed by b3-GalNAc attachment by B3GALNT2 and subse-
quently SGK196-catalyzed mannose phosphorylation. Our LC-MS/
MS data provide the first evidence for the implicated presence of this
phosphorylated trisaccharide structure on Thr-317 in themucin-like
region of a-DG, which was previously identified as the formation site
of laminin-binding glycans (Fig. 4). In the present study, AGO61-
dependent GlcNAc modifications were detected on a-DG-Fc pre-
pared from cell lysates but not in those secreted into the medium
irrespective of HFaq treatment (Fig. 3a and Supplementary Fig. S4).
These results suggested that additional GalNAc-modifications
masked the GlcNAc residues during secretion. The elongation of
laminin-binding glycans based on a phosphorylated O-mannosyl
trisaccharide may be mediated by some uncharacterized glycosyl-
trasferases encoded for by some dystroglycanopathy-associated
genes.
While the mucin-like domain of a-DG possesses numerous ser-
ine/threonine residues as potential O-mannosylation sites32–35,
AGO61 promotes the GlcNAc modification of O-Man at specific
sites, as best exemplified by Thr-317 and Thr-319, for the formation
of laminin-binding glycans (Fig. 4). Furthermore, in a-DGs mutated
at these sites (T317A/T319A-a-DG373 and T379A-Dmucin1-Fc),
laminin-binding activity was lost even when LARGE was overex-
pressed, although it could be rescued solely by overexpressing
AGO61. These results indicated that functional a-DG glycosylation
was primed by an AGO61-dependent GlcNAc modification.
In summary, we demonstrated that AGO61 served as an essential
POMGnT by priming the formation of laminin-binding glycans on
a-DG. Our findings provide a critical missing link for understanding
the laminin-binding glycan structures displayed on a-DG and pro-
vide therapeutic insights for dystroglycanopathy.
Methods
cDNA construction. Expression plasmids for human IgG-Fc fused a-DG (a-DG-Fc)
and mouse LARGE fused with myc epitope were constructed as described
previously36. For the expression plasmid for mouse LARGE fused with HA tag, the
cording sequence of mouse LARGE was amplified by PCR and cloned into phCMV3
(Genlantis). For an AGO61 expression vector, the encoding sequence of mouse
AGO61 was amplified by PCR and cloned into pcDNA3.1/V5-His-TOPO (C-
terminal hexahistidine and V5 tags) (Invitrogen). Amino acid substitutions and
deletion mutants of a-DG (a-DG373, a-DG428, and a-DG485) were made using
standard PCR and genetic engineering techniques. These mutants were cloned into
pFC14K HaloTag CMV Flexi vectors (C-terminal HALO tags) (Promega). For
fukutin and FKRP expression vectors, the encoding sequences of mouse fukutin and
FKRP were amplified by PCR and cloned into C terminal p3XFLAG-CMV (sigma)
and pSecTag2 (Invitrogen), respectively.
Antibodies. We used the following primary antibodies in this study: anti-AGO61
monoclonal antibody (mAb) (Atlas Antibodies AB); anti-O-GlcNAc (CTD110.6)
mAb (Cell Signaling Technology); anti-O-GlcNAc (HGAC85) mAb (Novus
Biologicals); anti-Halo mAb (Promega); anti-laminin polyclonal antibody (pAb)
(Sigma); anti-Myc mAb and IIH6 mAb (Millipore); anti-HA mAb (Nakalai Tesque);
anti-Fc pAb (Jackson ImmunoResearch); anti-b-DG mAb (Novocastra); and a-DG
core pAb (goat polyclonal antibody against the C-terminal domain if the a-DG
polypeptide)27. The following secondary antibodies were used for Western blot
analysis: horseradish peroxidase (HRP)-conjugated anti-rabbit IgG mAb
(Invitrogen); HRP-conjugated anti-mouse IgM mAb (Thermo Scientific); and HRP-
conjugated anti-mouse IgG mAb (Invitrogen).
Generation of AGO61 mutant mice. AGO61 mutants (Acc. No. CDB0628K: http://
www.cdb.riken.jp/arg/mutant%20mice%20list.html) were generated as described at
http://www.cdb.riken.jp/arg/Methods.html (Fig. S1 in Supporting Information). The
described genotypes were consistently observed irrespective of their ES cell clone of
origin, number of successive brother–sister mating generations, or backcrossing with
C57BL/6J mice (more than 10 generations). PCR genotyping of AGO61 alleles was
performed using Ex Taq polymerase (Takara) and the following primers as indicated
in Fig. S2 (Supporting Information): an AGO61-specific forward primer (AgoF
59-GTTGGTGGGCTAGGCAGATA-39); a neo-specific forward primer (NeoF
59-TCGCCTTCTTGACGAGTTCT -39); and a common reverse primer (CoR
59-CCTCCTGGTTGGATTTGAGA-39).
Mice. All animal treatments and experiments were done in accordance with the
guidelines and regulations of Nagoya City University. The protocol was approved by
the Committee for Animal Experiments of the Graduate School of Pharmaceutical
Sciences, Nagoya City University.
Cell culture and transfection. Neuro2a, COS1, and COS7 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies) supplemented
with 10% fetal bovine serum (FBS) in 5% CO2 at 37uC. For cDNA transfection, cells
were grown overnight and transfected using Lipofectamine 2000 (Life Technologies)
according to the manufacturer’s instructions.
Mouse embryo fibroblasts (MEFs) were prepared from individual AGO61 mutant
and wild-type embryos at embryonic day 13.5. An embryo without a head and
internal organs was minced and treated with 0.1% trypsin at 37uC for 30 min. These
cells were grown andmaintained inDMEM containing 10% FBS. Rescue experiments
were conducted with AGO KO MEFs using expression vectors for AGO61 and its
mutants with loss of function mutations (R158H and R445stop) using an NEPA21
electroporator (NEPA Gene).
Purification of HALO-tag fused proteins. Recombinant a-DG mutants were
purified using HaloLink resin (Promega). A HALO-tag was removed by proteolytic
cleavage using HaloTEV protease (Promega) according to the manufacturer’s
instructions. Purified proteins were separated by SDS-PAGE and subjected to silver
staining or Western blotting.
Western blotting and laminin overlay. Western blotting and laminin overlay were
performed as described previously36,37.
HFaq treatment. To hydrolyze phosphoester linkages, lysates of brain tissues were
treated with ice-cold 48%HFaq (WAKO) at 0uC for 16 h. After removing HFaq with
N2 gas, the resulting lysates were subjected to SDS-PAGE followed by Western blot
analysis. After SDS-PAGE, proteins were transferred onto PVDF membranes. The
membranes were incubated with ice-cold 48%HFaq at 4uC for 16 h. Control samples
were prepared similarly and treated with ice-cold water. The membranes were then
washed thrice with ice-cold water to remove residual HF and subjected to laminin
overlay assay or immunoblotting.
Glycosidase treatments. Recombinant a-DG was treated with b-N-
acetylhexosaminidase (New England Biolabs), b-N-acetylglucosaminidase (New
England Biolabs), or a-N-acetylgalactosaminidase (New England Biolabs) according
to the manufacturer’s instructions. These specimens were subjected to Western blot
analysis with an anti-O-GlcNAc antibody, CTD110.6.
LC-MS/MS and data analysis. In-gel tryptic digestion of recombinant proteins was
performed as previously described37. Extracted peptides were solubilized in 0.1%
formic acid and analyzed by nanospray LC-MS2 using a nanoACQUITY UPLC
System (Waters, Milford, MA, USA) coupled to an LTQ-Orbitrap Velos (Thermo
Scientific) through a PicoView (PV550, New Objective, Woburn, MA, USA)
nanospray interface. Peptide mixtures were loaded onto a 75 mm 3 250 mm
nanoACQUITY UPLC BEH130 column packed with C18 resin (Waters, Milford
USA) and separated at a flow rate of 300 nl/min using a linear gradient of 5%–50% of
solvent B (95% acetonitrile with 0.1% formic acid) in 80 min, followed by a sharp
increase to 85% B in 1 min and held at 85% B for another 10 min. Solvent A was 0.1%
formic acid in water. The data acquisition cycle included a full MS scan (m/z 400–
2000) recorded in the Orbitrap analyzer at 30,000 resolution, followed by data
dependent MS2 acquisition of the 20 most intense peptide ions in the linear ion trap.
Precursor ion isolation width was set at 3 Th and all singly charged precursors were
excluded. The automatic gain control (AGC) targets for Orbitrap fullMS and ion trap
MSn were set at 1 3 106 and 1 3 104, respectively. All MS/MS raw data were
processed using DeconMSn version 2.2.2.2 and directly searched against the a-DG
protein sequence using the Mascot Daemon 2.4 server with the following criteria:
trypsin digestion; fixed modification set as carbamidomethyl (Cys); variable
modifications set as oxidation (Met), Hex (Thr/Ser), HexNAc (Thr/Ser), and
PhophoHex (Thr/Ser); up to one missed cleavage allowed; and mass accuracy of
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10 ppm for the parent ion and 0.60 Da for fragment ions. Closely eluting
glycopeptides corresponding to other glycoforms were further identified manually by
inspecting the raw data.
Semi-quantitative RT-PCR. Semi-quantitative RT-PCR was done as described
previously36. In brief, total RNAwas isolated from embryonic brains at embryonic day
17.5 carrying wild-type and mutant genotypes using TRIzol reagent (Life
Technologies). cDNAs were synthesized from the total RNAs as templates using
SuperScriptIII reverse transcriptase (Life Technologies). To determine mRNA
expression levels, PCR was done with the following primer pairs: DAG1: GCCA-
GATTCGCCCAACACTGACAAT and CCACCCAGGCATCTACCCTGTCAAT;
LARGE: GTCAGATGCAGAAGCCCAGCAGTTC and TGGGGAAAGAGAGT-
CTGTAGCGCAG; LARGE2: CGAGAGCTGCTCACTCTGAT and GGCATC-
CAAAGAGCTCTCTT; POMGnT1: TCGTGGGACGAAAAGGAGGTCC and
TGGGCCGGTTCCCTGCAATG; POMT1: TTGCCCGCATCACCCAAGGC and
GGCTGCGACATCGTGCGTGTT; POMT2: TTGCTGGCTACCTGAGCGGG and
AGGGGGCAGAGAAAGGCCTGTT; fukutin: CACTATTTGTCTGCAAGG-
AATGGAC and CTTGCTTTCAGTCTTTAGGCATTGA; FKRP: CTTC-
TGTCCCGCTTCAGTTC and AACCAGAGAGAGCCCAGTCA; B3gnt1:
AATCAGCCAGGCTTGTGAGC and TGGAGGCATGTTTCTTACCCC; ISPD:
TGGATCACATAGGCGGAGAC and GCTTCTGCTCATCCTGTGAGT; and
GAPDH: GGAAGGGCTCATGACCACAGTCCAT and CATACTTGGCAGGTT-
TCTCCAGGCG. PCR products were analyzed by agarose gel electrophoresis using
1% agarose gels.
Immunohistochemistry. Mouse embryonic brains at embryonic day 17.5 carrying
wild-type and mutated genotypes were fixed in phosphate-buffered saline containing
4% paraformaldehyde, embedded in O.C.T. compound (Sakura Finetechnical,
Tokyo, Japan), and frozen in liquid nitrogen. Cryosections (20 mm thick) were
prepared from the embedded brains and stained with anti-nestin and anti-laminin
antibodies. For a secondary antibody, Alexa Fluor 488-conjugated anti-goat IgG
antibody (Life Technologies) or Alexa Fluor 546-conjugated anti-rabbit IgG antibody
(Life Technologies) was used. Nuclei were stained with DAPI (1 mg/mL; Sigma-
Aldrich). Stained sections were photographed under a Nikon Eclipse TE300
fluorescent microscope (Nikon).
Immunocytochemistry. Neuro2a cells transfected with an AGO expression vector
and subcellular localization vectors (pDS-red2-ER or pAcGFP-Golgi; Clontech, Palo
Alto, CA) were plated onto chamber slides (Nalge Nunc International) and fixed in
PBS containing 4% paraformaldehyde. Cells were treated for 2 h with PBS containing
3% fetal bovine serum and 0.1% Triton X-100, and then stained with primary
antibodies, including an anti-AGO61 monoclonal antibody (BD Biosciences, San
Jose, CA), and a secondary antibody, an anti-rabbit IgG antibody conjugated with
Alexa Fluor 488 or Alexa Fluor 595 (BD Biosciences). Nuclei were stained with 2 mg/
mL of Hoechst 33258 (Sigma-Aldrich). Stained cells were photographed under a
Nikon Eclipse TE300 fluorescent microscope.
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